Acquired Company

Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals on 9/26/2023 for approximately US$462 million, including the assumption of debt and CVR liabilities.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use. Show more

75 Park Plz Ste 4, Massachusetts, 02116-3934, US

https://paratekpharma.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$2.23

Open

$2.23

Volume

N/A

Day Range

$2.23 - $2.23

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

11.70%

Institutional Own.

55.08%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nuzyra (Omadacycline) Details Pneumonia, Community acquired bacterial pneumonia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nuzyra (Omadacycline) Details Bacterial infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seysara (Sarecycline) Details Inflammatory Acne (Acne Vulgaris)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Omadacycline (Nuzyra) Details Intestinal infection, Stomach, Digestive tract, Nontuberculous mycobacteria infections	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.